As the term implies, levodopa-induced dyskinesia (LID) is a complication of chronic use of levodopa, the gold standard of Parkinson’s disease (PD) treatment. Surveyed neurologists estimate that 40% of their patients suffer from LID, which is often disabling and painful, impacting quality of life and increasing fall risk. For decades, the only drug for LID has been immediate-release amantadine—now long generic—but it is not specifically approved for LID and has an unfavorable side-effect profile. Now, the treatment of PD–LID is evolving, thanks to the recent FDA approval of Gocovri for LID and research suggesting Xadago may have a positive impact. Understanding prescriber perceptions of available options and the drivers of clinical decision-making in PD–LID will help drug developers identify levers for new product positioning and differentiation and gauge unmet clinical need for further innovations in this arena.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 62 U.S. and 30 European neurologists fielded in December 2018.
Key drugs covered: Amantadine, Gocovri, Xadago.
Key metrics included:
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.